DNDN has a similar drug and effect, both extend life by 4 to 5 months. DNDN owns 100% of their drug and keeps all of the profit. MDVN owns half of the drug and must pay a royalty. DNDN had revenue of $65M, while MDVN had revenue of $45 M. DNDN is further along in extending application and the executives haven't sucked the company dry in free stock options.
First of all Provenge isn't a drug at all, it's an immunotherapy. It has to be custom made for each individual, which is why the profit margin is relatively low. The oncologist has to put out around $80,000 for a single course of treatment and hope he gets reimbursed. Xtandi is a one-size-fits-all pill with a profit margin in excess of 90%. Other than that, they're just the same.